Model-informed precision dosing in inflammatory bowel diseases

Recent advances in therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) are reshaping treatment strategies for inflammatory bowel diseases (IBDs).MIPD uses pharmacokinetic/pharmacodynamic (PK/PD) models that integrate patient data to optimize drug dosing.Recent studies highlight the significance of therapeutic thresholds in guiding dose adjustments, aiming to improve patient outcomes.Emerging technologies such as point-of-care assays and self-sampling devices facilitate more precise and real-time monitoring of drug levels.Effective MIPD in prospective TDM will require enhancement of models with biomarker data and facilitate deeper understanding of exposure–response relationships. Therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease (IBD) primarily aims to optimize dosing. However, several unmet needs remain. These include the identification of optimal drug concentrations, accounting for variability in pharmacokinetics (PK) and pharmacodynamics (PD), and the frequent delays between sampling and clinical decision-making. Recent technical advances, such as population PK/PD modeling and model-informed precision dosing (MIPD) tools developed from such models, as well as point-of-care (POC) and self-sampling assays and novel software programs, offer potential solutions. Successful implementation of these innovations may help to establish MIPD for patients with IBD. This would enable personalized dosing, advancing a one-size-fits-all approach to TDM that currently is inadequate to fulfill the needs for every patient with IBD. Therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease (IBD) primarily aims to optimize dosing. However, several unmet needs remain. These include the identification of optimal drug concentrations, accounting for variability in pharmacokinetics (PK) and pharmacodynamics (PD), and the frequent delays between sampling and clinical decision-making. Recent technical advances, such as population PK/PD modeling and model-informed precision dosing (MIPD) tools developed from such models, as well as point-of-care (POC) and self-sampling assays and novel software programs, offer potential solutions. Successful implementation of these innovations may help to establish MIPD for patients with IBD. This would enable personalized dosing, advancing a one-size-fits-all approach to TDM that currently is inadequate to fulfill the needs for every patient with IBD.